First human test of new drug for Alzheimer's risk in down syndrome halted early
Disease control
Terminated
This early-stage study aimed to check the safety and how the body processes a new drug called ION269 in adults with Down syndrome who have brain amyloid, a protein linked to Alzheimer's disease. Only one person was enrolled before the study was stopped. The main goal was to see i…
Phase: PHASE1 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC